RT Journal Article
SR Electronic
T1 Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 587444
DO 10.1101/587444
A1 Ana C. Vicente
A1 Francisca H. Guedes-da-Silva
A1 Carlos H. Dumard
A1 Vivian N. S. Ferreira
A1 Igor P. S. da Costa
A1 Ruana A. Machado
A1 Fernanda G. Q. Barros-Aragão
A1 Rômulo L. S. Neris
A1 Júlio S. Dos-Santos
A1 Iranaia Assunção-Miranda
A1 Claudia P. Figueiredo
A1 André A. Dias
A1 Andre M. O. Gomes
A1 Herbert L. de Matos Guedes
A1 Andrea C. Oliveira
A1 Jerson L. Silva
YR 2019
UL http://biorxiv.org/content/early/2019/03/25/587444.abstract
AB Zika virus (ZIKV) emerged as an important infectious disease agent in Brazil in 2016. Infection usually leads to mild symptoms but severe congenital neurological disorders and Guillain-Barré syndrome have been reported following ZIKV exposure. The development of an effective vaccine against Zika virus is a public health priority, encouraging the preclinical and clinical studies of different vaccine strategies. Here, we describe the protective effect of an already licensed attenuated yellow fever vaccine (17DD) on type-I interferon receptor knockout mice (A129) and immunocompetent (BALB/c) mice infected with ZIKV. Yellow fever virus vaccination results in robust protection against ZIKV, with decreased mortality in the A129 mice, a reduction in the cerebral viral load in all mice, and weight loss prevention in the BALB/c mice. Despite the limitation of yellow fever (17DD) vaccine to elicit antibody production and neutralizing activity against ZIKV, we found that YF immunization prevented the development of neurological impairment induced by intracerebral virus inoculation in adult. Although we used two vaccine doses in our protocol, a single dose was protective, reducing the cerebral viral load. Different Zika virus vaccine models have been tested; however, our work shows that an efficient and certified vaccine, available for use for several decades, effectively protects mice against Zika virus infection. These findings open the possibility for using an available and inexpensive vaccine to a large-scale immunization in the event of a Zika virus outbreak.